
Publication
Strategic asset search and evaluation in biopharma
Biotechnology companies are primarily built around platform technologies and focused on asset specific value creation.
Singapore | Publication | April 2025
In a landmark decision (CIX v DGN [2025] SGCA 10), the Singapore Court of Appeal addressed the issue of whether the extended doctrine of res judicata (a doctrine which bars re-litigation) (extended doctrine) could be invoked by a party who was neither a party to the earlier arbitration proceedings nor a party to the arbitration agreement.
The Singapore Court of Appeal (SGCA) found that the extended doctrine can apply to situations where (a) there is no identity of parties and (b) where the earlier proceedings are in arbitration and the later proceedings are before a court of competent jurisdiction. Thus, the extended doctrine can be invoked by non-parties to arbitration proceedings to stave off repeated claims in subsequent court proceedings.
The appellant (the Seller) entered into a Sale and Purchase Agreement (SPA) with a corporate entity (the Buyer) for the sale of his shares in a company. Part of the sale price for the shares was to be determined by a valuation exercise. To carrying out this valuation exercise, the parties agreed to appoint the respondent (Phoenix) as the independent human resource consultant, on the condition that Phoenix provide a declaration of no conflict of interest. Consequently, Phoenix issued a declaration of no conflict of interest to the Buyer and the Seller.
The arbitration proceedings between the Seller and the Buyer
Phoenix issued seven market pricing and compensation data reports (the Phoenix Reports). The Seller and the Buyer disagreed on the figures to be adopted from the Phoenix Reports to determine the valuation of the shares. The Seller then referred the dispute with the Buyer to arbitration proceedings. Phoenix was neither a party to the arbitration agreement nor the arbitration proceedings.
In the arbitration, the Tribunal accepted the median market benchmark in the Phoenix Reports, i.e. the position advanced by the Buyer’s expert in its First Partial Award. The Seller then unsuccessfully applied to set aside certain findings in the Tribunal’s First Partial Award. The Seller appealed the High Court’s decision.
While the appeal was pending, the Seller made an application in the arbitration raising allegations of corruption against Phoenix and/or the Buyer and asked the Tribunal to determine whether it was safe to rely on the Phoenix Reports (the Corruption Application). The Seller sought to argue that Phoenix lacked independence, and the Buyer deliberately concealed this fact by misleading the Tribunal and the Seller. Ultimately, the Tribunal rejected the Corruption Application, finding that “any such allegation could and ought reasonably to have been raised at the evidentiary hearing before the [First] Partial Award was issued”. The Seller did not seek to set aside the Tribunal’s decision in this respect.
The commencement of Suit 885 before the Singapore Court
The Settlement
On or around June 2024 and sometime after Suit 885 was dismissed, it was disclosed that the Seller and the Buyer had reached a settlement (Settlement). As a result of the Settlement, all arbitration and court proceedings between the Seller and the Buyer were discontinued or terminated.
The SGCA dismissed the appeal, finding:
Ascendant Legal successfully acted for the defendant/respondent in proceedings before the Singapore High Court and the Court of Appeal to stave off the claimant/appellant’s claims. Indemnity costs were awarded to the defendant/respondent in both the High Court and Court of Appeal proceedings.
Publication
Biotechnology companies are primarily built around platform technologies and focused on asset specific value creation.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright US LLP 2025